[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647874":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":61,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Deraya University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Triamcinolone Acetonide Nanocapsules","EXPERIMENTAL","Participants assigned to this arm will receive topical triamcinolone acetonide-loaded polymeric nanocapsules as postoperative nasal therapy following endoscopic nasal surgery",[13],"Drug: Triamcinolone Acetonide-Loaded Polymeric Nanocapsules",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal Saline Irrigation","ACTIVE_COMPARATOR","Participants assigned to this arm will receive standard postoperative normal saline nasal irrigation following endoscopic nasal surgery.",[19],"Other: Normal Saline Nasal Irrigation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Triamcinolone Acetonide-Loaded Polymeric Nanocapsules","Triamcinolone acetonide incorporated into polymeric nanocapsules prepared using a nanoprecipitation method will be administered topically to the postoperative nasal cavity.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal Saline Nasal Irrigation","Participants will receive postoperative nasal irrigation with 0.9% sodium chloride solution.",[15],[32],{"name":33,"affiliation":5,"role":34},"Sally Mansour Helmy","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+20 102 692 0921","aliaa.gamal@deraya.edu.eg",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":39},"Aliaa Gamal Hussein","+201003041632",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Deraya university, faculty of pharmacy","RECRUITING","Minya","Menia Governorate","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],30.75813,28.09193,{"lat":55,"lon":54},[58],{"name":59,"role":37,"phone":60,"phoneExt":26,"email":39},"Aliaa Gamal Hussien","+20 1003041632",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100647874","phase-2-triamcinolone-nanocapsules-after-endoscopic-nasal-surgery-100647874",false,"NCT07714525","Triamcinolone Nanocapsules After Endoscopic Nasal Surgery","Clinical Evaluation of Triamcinolone Acetonide-loaded Nanoparticles For Nasal Postoperative Application","Inclusion Criteria\n\n* Adults aged 18 to 60 years.\n* Patients scheduled to undergo one of the following procedures:\n* Functional endoscopic sinus surgery\n* Endoscopic turbinoplasty\n* Endoscopic septoplasty\n* Diagnosis of chronic rhinosinusitis and\u002For nasal polyps requiring surgical intervention.\n* Ability and willingness to provide written informed consent.\n* Ability and willingness to comply with study treatment and scheduled follow-up visits.\n\nExclusion Criteria\n\n* Known hypersensitivity to triamcinolone acetonide.\n* Known hypersensitivity to any component of the polymeric nanocapsule formulation.\n* Systemic contraindication to corticosteroid therapy.\n* Active severe nasal or sinonasal infection at the time of enrollment or treatment.\n* Pregnancy or breastfeeding, if excluded in the approved protocol.\n* Uncontrolled diabetes mellitus, if corticosteroid exposure is considered clinically relevant.\n* Immunosuppression or use of immunosuppressive therapy.\n* Recent use of systemic or intranasal corticosteroids within the protocol-defined washout period.\n* Participation in another clinical trial.\n* Any medical or psychiatric condition that may interfere with informed consent, study treatment, or follow-up.\n* Inability to complete the required questionnaires or follow-up visits.","ALL","18 Years","60 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This randomised, single-masked, parallel-group clinical trial will evaluate the efficacy and safety of a topical triamcinolone acetonide-loaded polymeric nanocapsule formulation for postoperative care following endoscopic nasal surgery.\n\nParticipants will receive either the investigational triamcinolone acetonide-loaded nanocapsule formulation or standard normal saline nasal irrigation. Postoperative nasal healing, inflammation, patient-reported sinonasal symptoms, postoperative complications, and corticosteroid-related adverse effects will be compared between the two groups.",[81,82,83],"Chronic Rhinosinusitis (CRS)","Nasal Polyps","Postoperative Healing After Endoscopic Nasal Surgery",[85,86,87,88],"Triamcinolone acetonide","Nanocapsules","Polymeric nanocapsules","Endoscopic nasal surgery","2026-07-24",{"date":91,"type":92},"2026-07-27","ACTUAL",{"date":94,"type":92},"2026-05-01",{"date":96,"type":75},"2027-06-01",{"name":5,"class":6},1]